Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Bexotegrast · PLN-74809

Small molecule · developed by Pliant Therapeutics

Phase 2 Most advanced trial (none active)
PLRX Developer
1 Registered trials

What is Bexotegrast?

Bexotegrast (PLN-74809) is an investigational agent studied in idiopathic pulmonary fibrosis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
PLN-74809
Drug type
Small molecule
Therapy area
Respiratory
Developer
Pliant Therapeutics, Inc. (PLRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT06097260 Phase 2 Idiopathic Pulmonary Fibrosis Terminated PLRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Idiopathic Pulmonary Fibrosis

More from Pliant Therapeutics

Follow PLRX, the company behind Bexotegrast

See PLRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PLRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.